Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare head and neck cancer, which previously relied on chemotherapy. India joins China and the US in offering this groundbreaking therapy that reduces risk of progression or death by 48%.Original Article